Glucosyl sphingosine is a lipid of Sphingolipids (SP) class. Glucosyl sphingosine is associated with abnormalities such as Sphingolipidoses, Globoid cell leukodystrophy, Sandhoff Disease, Tay-Sachs Disease and Fabry Disease. The involved functions are known as Apoptosis, Acetylation, Infiltration, kinase activity and energy pathways. Glucosyl sphingosine often locates in Lysosomal and Protoplasm. The associated genes with Glucosyl sphingosine are MAPT gene, GALC gene, HEXA gene, PICK1 gene and ELF3 gene. The related lipids are lysoganglioside G(M2), Ganglioside GA2, Lysophosphatidylcholines and globotriaosyl lysosphingolipid.
To understand associated biological information of Glucosyl sphingosine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucosyl sphingosine is suspected in Globoid cell leukodystrophy, Sphingolipidoses, Sandhoff Disease, Tay-Sachs Disease, Fabry Disease and other diseases in descending order of the highest number of associated sentences.
| Disease | Cross reference | Weighted score | Related literature |
|---|
We collected disease MeSH terms mapped to the references associated with Glucosyl sphingosine
| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Leukodystrophy, Globoid Cell | D007965 | 6 associated lipids |
| Nerve Degeneration | D009410 | 53 associated lipids |
| Gaucher Disease | D005776 | 13 associated lipids |
| Parkinson Disease | D010300 | 53 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
| Location | Cross reference | Weighted score | Related literatures |
|---|
| Function | Cross reference | Weighted score | Related literatures |
|---|
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
| Gene | Cross reference | Weighted score | Related literatures |
|---|
There are no associated biomedical information in the current reference collection.
| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Burrow TA et al. | CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. | 2015 | Mol. Genet. Metab. | pmid:25219293 |
| Fuller M et al. | Rapid, single-phase extraction of glucosylsphingosine from plasma: A universal screening and monitoring tool. | 2015 | Clin. Chim. Acta | pmid:26232157 |
| Mirzaian M et al. | Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard. | 2015 | Blood Cells Mol. Dis. | pmid:25842368 |
| Aflaki E et al. | Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. | 2014 | Sci Transl Med | pmid:24920659 |
| Gaspar P et al. | Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. | 2014 | J. Lipid Res. | pmid:24212238 |
| Angka L et al. | Glucopsychosine increases cytosolic calcium to induce calpain-mediated apoptosis of acute myeloid leukemia cells. | 2014 | Cancer Lett. | pmid:24631520 |
| Welford RW et al. | Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study. | 2014 | PLoS ONE | pmid:25479233 |
| Sardi SP et al. | Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. | 2013 | Proc. Natl. Acad. Sci. U.S.A. | pmid:23297226 |
| Sun Y et al. | Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease. | 2013 | PLoS ONE | pmid:23520473 |
| Rolfs A et al. | Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. | 2013 | PLoS ONE | pmid:24278166 |